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Recently, it has been described that programmed cell death protein 1 (PD-1)
overexpressing melanoma cells are highly aggressive. However, until now it has not been
defined which factors lead to the generation of PD-1 overexpressing subpopulations.
Here, we present that melanoma-derived exosomes, conveying oncogenic molecular
reprogramming, induce the formation of a melanoma-like, PD-1 overexpressing cell
population (mMSCPD-1+) from naïve mesenchymal stem cells (MSCs). Exosomes and
mMSCPD-1+ cells induce tumor progression and expression of oncogenic factors
in vivo. Finally, we revealed a characteristic, tumorigenic signaling network combining
the upregulated molecules (e.g., PD-1, MET, RAF1, BCL2, MTOR) and their upstream
exosomal regulating proteins and miRNAs. Our study highlights the complexity of
exosomal communication during tumor progression and contributes to the detailed
understanding of metastatic processes.
Keywords: PD-1, exosome, melanoma/tumor progression, stem cell, reprogramming, signalization pattern,
metastasis
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INTRODUCTION
Heterogeneous tumor tissue is comprised of a wide variety
of collocated cells. Their spatiotemporal co-existence facilitates
direct communication between them. Cancer cells contribute to
tumor niche formation not only by soluble factor production
and receptor-ligand interactions (1), but also by releasing vesicles
whose molecular contents add up to a complex information
package. Previous studies demonstrated that cultured human
tumor cells release extracellular vesicles such as exosomes of 20–
120 nm diameters (2). Among others, exosomes carry structural
and signaling proteins, MHC molecules, cell surface molecules
typically associated with apoptosis, and mRNAs/miRNAs with
multiple functions (3). Therefore, these exosomal-molecular-
patterns, as unique entities of the complex intercellular
communication, are not independent of the quality or state of
the mother cell (4, 5). Exosomes have been recognized long ago,
but their identification, characterization, and isolation are still
under intense investigation. Further, whereas the definition of
exosomes is based on the pathway of biogenesis, oncosomes form
a functional class of extracellular vesicles. Indeed, oncosomes are
suggested being capable of carrying and conveying tumor-related
information (6) and might have a significant role in formation of
tumor microenvironment (7).
Mesenchymal stem cells (MSCs) were first described as
stromal cells of the bonemarrow withmultipotent differentiation
potential and characteristic immunomodulatory effects (8). In
relation to their immunological and differentiation properties,
there is a debate about the role of MSCs in tumor progression (9).
Indeed, the cellular fate could depend on the cancer type and also
on the status of the affected MSCs. Activated MSCs can secrete
pro-angiogenic soluble factors and are able to differentiate to
vessel wall associated cells (10) or to cancer associated fibroblasts
(CAFs) (11). Furthermore, Baglio et al. showed that tumor
secreted extracellular vesicles promote osteosarcoma progression
via TGFβ signaling induced IL-6 production by MSCs (12).
Moreover, Peinado et al. demonstrated that exosomes from
highly metastatic melanomas increase the metastatic behavior
of primary tumors by permanently educating bone marrow
progenitors through the receptor tyrosine kinase MET (13).
Malignant melanoma is a highly invasive, metastatic cancer
with poor prognosis and survival rate. Since melanoma has been
long recognized as a highly immunogenic tumor, therapeutic
approaches target different immunological mechanisms to treat
patients with this aggressive skin cancer. In the past decade,
besides IL-2 and CTLA-4 therapies, the PD-1:PD-L1 blockade
proved to be an effective treatment in metastatic melanoma
(14). Programmed cell death protein 1 (PD-1), mainly expressed
by immune cells such as activated T cells, dendritic cells and
macrophages is a cell surface receptor with a central role in
modulation of T cell responses. PD-1 binding to its ligand,
PD-L1, can result in apoptosis and anergy of immune cells.
Notably, PD-1 expression is not a default property of
melanoma cells. Of further importance, recently Kleffel
et al. demonstrated that PD-1 overexpressing melanoma cell
subpopulations are especially aggressive, and that melanoma
PD-1:PD-L1 interactions modulate mTOR signaling, whereby
they interfere with programmed cell death (15). This work
is remarkably instrumental with respect to the consequences
of PD-1 overexpression and experimental inhibition of PD-1
functions (Pdcd1-shRNA or anti-PD-1 antibody). However,
it does not define the factors the activation of which lead to
the generation of PD-1 overexpressing subpopulations. This
question, though, is an especially intriguing one, if one considers
that one of the most effective immunotherapies available today
is based on the blockade of the aforementioned PD-1:PD-L1
interaction (16).
Based on the above, in the current study, we
aimed at specifically and systematically addressing the
following questions:
1. Can we unambiguously define the cellular and molecular
signs of melanoma-derived exosome-induced, intercellular
communication-mediated malignant transformation of
MSC cultures?
2. Can we detect the melanoma-derived exosome-induced
tumor progression in vivo?
3. What alteration can be detected in the expression of PD-1, a
melanoma progression marker and therapeutic target, upon
exposure to melanoma-derived exosomes?
Here, we present the first piece of evidence that melanoma
exosomes, by conveying a complex oncogenic molecular
reprogramming, induce the formation of a PD-1 overexpressing
cell population (melanoma-like MSCPD-1+; mMSCPD-1+)
from naïve MSCs. These mMSCPD-1+ cells represent a
new entity with melanoma-like gene expression profile and
phenotypic properties. Further, exosomes and exosome-
activated mMSCPD-1+ cells induce rapid tumor progression in
vivo, due to their strong expression of oncogenic dominance
factors and decreased susceptibility to programmed cell death.
MATERIALS AND METHODS
Cell Culture and Cell Line
B16F1 mouse melanoma cell line was obtained from ECACC
and cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Lonza, Basel, Switzerland) containing 10% fetal bovine serum
(FBS) (Euroclone, Milano, Italy), 1% sodium pyruvate, 1% MEM
non-essential amino acids, 1% MEM vitamin solution, 2mM
L-glutamine, and 1% Penicillin-Streptomycin-Amphotericin B
Mixture (all from Lonza).
Murine MSCs were isolated from C57BL/6N (Charles River
Laboratories, Sulzfeld) 8 week-old male mice (17). Abdominal
inguinal fat pads were excised, rinsed with RPMI 1640 medium,
transferred to sterile tissue culture dishes and mechanically
dissociated. The dissociated tissue was resuspended in RPMI
1640 containing 100µg/ml collagenase (Sigma-Aldrich, St. Louis,
MO) and incubated at 37◦C for 50min. Collagenase was
neutralized with a growth medium containing 10% FBS. After
centrifugation at 470 g for 15min, cell pellets were resuspended
and washed in the culture medium. After the centrifugation,
cell pellets were resuspended in complete MesenCult medium
(Stemcell Technologies, Vancouver, British Columbia, Canada)
and filtered through a 100µm cell strainer (BD Biosciences,
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Franklin Lakes, NJ) to tissue culture dishes, and cultured for 48 h
at 37◦C in 5% CO2 and 90% humidity. Unattached cells and
debris were then removed and fresh medium was added to the
adherent cells. The cells were cultured to 80% confluence before
being released with trypsin–EDTA and sub-cultured.
Purity of MSC cultures were checked by flow cytometry
analysis using the Mouse Multipotent Mesenchymal Stromal
Cell Marker Antibody Panel (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions.
Isolation and Characterization of the
Melanoma-Derived Exosomes
Exosome Isolation by Filtration and Differential
Centrifugation
Exosomes were isolated by adapting the protocol of Peinado
et al. (13) from melanoma cell culture supernatant. B16F1
supernatants were harvested, supplemented by complete protease
inhibitor cocktail (Roche, Mannheim, Germany) and centrifuged
at 780 g for 5min at 4◦C to remove intact cells. Then, the
supernatants were centrifuged at 3,900 g for 15min at 4◦C and
filtered through a 0.2µm membrane (Millipore, Billerica, MA)
to remove larger cell fragments and microvesicles. Exosomes
were pelleted by ultracentrifugation at 150,000 g (T-1270 rotor
at 40,500 rpm) for 1 h at 4◦C. The pellet was washed twice and
resuspended in DPBS and stored at−80◦C.
The concentration of exosomal proteins was determined
using a Pierce BCA Protein assay kit (Thermo Fisher Scientific,
Waltham, MA) and a Benchmark Microplate Reader (Bio-Rad,
Hercules, CA) according to the manufacturer’s instructions.
Determination of Shape and Size of the Isolated
Vesicles
Scanning electron microscopy (SEM)
Five microliters of isolated exosomes in DPBS were spotted
on glass coverslips coated with 0.01% Poly-L-Lysine (Sigma-
Aldrich) and incubated overnight at 4◦C. Using sterile forceps,
coverslips were transferred into a plastic plate. Exosomes were
fixed by gently adding 2% paraformaldehyde buffer pH 7.2
diluted in DPBS for 30min. The coverslips were washed twice
with DPBS and dehydrated with a graded ethanol series (40,
60, 80, and 100% ethanol, each for 5min). The samples were
dried with a critical point dryer (QUORUM K850, Quorum
Technologies Ltd, Laughton, UK) and the coverslips were
mounted onto a microscope stub at a time using carbon tape,
followed by 7 nm gold coating (QUORUM Q150, Quorum
Technologies Ltd) and observed under a field-emission scanning
electron microscope (JEOL JSM-7100F/LV).
Atomic force microscopy (AFM)
Exosomes were let to adsorb to the freshly cleaved muscovite
mica (SPI-ChemTM Mica Sheets, Structure Probe, Inc., West
Chester, PA) surface directly fromDPBS. All AFMmeasurements
were carried out with an Asylum MFP-3D head and Molecular
Force Probe Controller (Asylum Research, Santa Barbara, CA),
using Asylum Research MFP-3D program (version 15.09.112)
written in Igor Pro software (version 6.37, Wavemetrics, Lake
Oswego, OR). Image procession and data calculation were made
using the same software. Silicon rectangular cantilevers (OMLC-
AC240TS, Olympus Optical Co., Ltd., Tokyo, Japan) with the
typical spring constant of 2 N/m were used in dry condition and
silicon nitride rectangular cantilevers with “V” shaped tips (Bio-
Lever BL-RC150VB, Olympus Optical Co. Ltd.) with the typical
spring constant of 0.03 N/m in buffer solution. Typically, 512
× 512 points was taken at 1 line/s scan rate. The measurements
presented here are amplitude images and height profile.
Detection of Exosomal Markers by Western Blotting
Protein samples were resuspended in 4x sample buffer (NuPAGE
LDS Sample Buffer (4X), NuPAGE Sample Reducing Agent
(10X), Thermo Fisher Scientific), boiled at 96◦C for 10min,
and immediately cooled on ice. Electrophoresis of the proteins
was performed using 4–12% Bis-Tris Protein Gels (NuPAGE
Novex, Thermo Fisher Scientific), ProSieve Color Protein
Markers (Lonza), and electrophoresis buffer (NuPAGE MOPS
SDS Running Buffer, Thermo Fisher Scientific) at 200V and
0.03A for 40 min.
The proteins of electrophoresed gels were transferred to
Immobilon transfermembrane (Millipore, Darmstadt, Germany)
using transfer buffer [NuPAGE Transfer Buffer (20X)] at 30V
and 170–110mA for 60min. Membranes were blocked in TBST
buffer (25mM Tris-HCl, 150mM NaCl, 0.05% Tween-20, pH
7.2) containing 5% non-fat milk for 60min at room temperature
(RT). After blocking, membranes were incubated with each
primary antibody in TBST buffer containing 1% non-fat milk
overnight at 4◦C.Membranes were washed three times for 10min
with TBST buffer and incubated for 60min at room temperature
with secondary antibody in TBST buffer containing 1% non-
fat milk. Membranes were washed three times for 10min with
TBST buffer.
For exosomal marker identification western blot analyses
were performed with an anti-CD63 polyclonal antibody (1:250
dilution; Biorbyt, Cambridge, UK) anti-CD9 monoclonal
antibody (clone EPR2949, 1:500 dilution, LifeSpan Biosciences,
Seattle, WA), anti-CD81 monoclonal antibody (clone: EAT2,
1:1,000 dilution, LifeSpan Biosciences, Seattle, WA), and
anti-HSP70 monoclonal antibody (clone: C92F3A-5, 1:8,000
dilution; Enzo Life Sciences, Farmingdale, NY), anti-rabbit IgG
HRP-Conjugated antibody (1:1,000 dilution, R&D Systems),
anti-Hamster IgG HRP-Conjugated antibody (1:30,000 dilution,
Thermo Fisher Scientific). Bound antibodies were visualized
by chemiluminescence using an ECL Plus Western Blotting
detection system (Advansta, Menlo Park, CA). Immunoreactive
signals were detected by using LI-CORODYSSEY Fc (Dual-mode
imaging system) imager followed by analysis with Odyssey v1.2,
Image Studio Lite v5.2.
Identification of Exosomal Proteins by Mass
Spectrometry
Exosomal proteins (24 µg) were separated in 4–12% Bis-Tris
Protein Gels and stained with Coomassie blue (0.1% Coomassie
Brilliant Blue R-250, 50% methanol and 10% acetic acid).
Each lane was cut to 12–12 equal bands and subjected to in-
gel digestion. Gel bands were diced to smaller pieces, and the
SDS and CBB dyes were washed out with 3 × 50 µl 25mM
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ammonium-bicarbonate (ABC)/50% Acetonitrile (AcN). After
reduction with DTT (1,4-dithiothreitol, Sigma-Aldrich; 20 µl,
10mM DTT in 25mM ABC) at 56◦C for 30min, and alkylation
with IAM (iodoacetamide, Sigma- Aldrich; 20 µl, 55mM IAM
in 25mM ABC) at RT in the dark for 30min, the gel samples
were dried in a vacuum centrifuge and after that rehydrated in
20 µl of trypsin (Sequencing Grade Modified Trypsin, Promega,
Fitchburg, WI; 5 ng/µl in 25mM ABC) and incubated at 37◦C.
The digestion was stopped after 4 h by lowering the pH of the
buffer below 3, by adding 2 µl of 10% formic acid. Tryptic
peptides were extracted from the gel with 3 × 50 µl of 2%
formic acid in 50% AcN and dried. Prior mass spectrometric
analysis, all samples were redissolved in 50–50 µl of 0.1%
formic acid (FA).
Samples were analyzed on an LTQ-Orbitrap Elite (Thermo
Fisher Scientific) mass spectrometer on-line coupled with a
nanoHPLC (nanoAcquity, Waters, Milford, MA) system. 5–5 µl
of the in-gel digests were loaded (for 3min at 8 µl/min flow,
using 0.1% FA in 3% Acetonitrile−97% water) onto a reversed
phase trap column (Waters, Symmetry C18, 0.180 × 20mm)
and separated on a C18 reversed phase (Waters, Milford, MA,
BEH300C18 1.7µm) nanocolumn (0.075 × 200mm). The flow
rate was 330 nl/min and a linear gradient was used from 3 to 40%
B in 37min (solvent A was 0.1% FA in water and solvent B was
0.1% FA in Acetonitrile).
The high voltage (1.2 kV) was applied through liquid junction
between the chromatographic column and the non-coated silica
nanospray emitter (NewObjective, Woburn, MA, 10µm tip
ID). The mass spectrometer operated in data-dependent mode:
the survey mass spectra were detected in the orbitrap with
high resolution (R = 60 k @ m/z: 400, mass range m/z: 380–
1,400) and the most abundant multiply charged 20 peaks were
selected for ion-trap fragmentation (NCE: 35%; activation q: 0.25;
activation time: 10ms; minimum signal intensity: 5,000 counts).
The MSMS spectra were detected in the ion trap. Dynamic
exclusion was used, the precursors were excluded for 15 s after
the first fragmentation event.
Data analysis: searchable peaklists (mgf format) were
extracted using ProteomeDiscoverer (ver:1.4 Thermo Fisher
Scientific) and subjected to database search on our in-house
ProteinProspector (ver: 5.14.1) search engine using the following
parameters: parent ion tolerant: 5 ppm; fragment ion tolerant:
0.6 Da; Cys carbamidomethylation was set as constant and Met
oxidation, cyclisation of peptide N-terminal Glu to pyroglutamic
acid, protein N terminal acetylation were set as variable
modifications. Only fully tryptic peptides were considered with
maximum of 2 missed cleavage sites. TheMus musculus and Bos
taurus protein sequences of the Uniprot (UniProtKB.06.11.2014)
database completed with human keratins and pig trypsin,
altogether 106,330 protein sequences were searched. For the false
discovery rate (FDR) estimation, the searches were performed
on the database concatenated with the randomized sequences.
Protein identification was accepted if the ProteinProspector
expectation value was <0.01 and the protein was identified
with at least 2 unique peptides (expectation value <0.05
and score higher than 15). FDR values were <1% in
all cases.
For functional validation, the resulted protein list was
analyzed by the “Core Analysis” function included in Ingenuity
Pathway Analysis (IPA, Quiagen Bioinformatics) software.
Isolation and Detection of Exosomal miRNAs
miRNA sequencing was performed using SOLiD Total RNA-
Seq lit for Small RNA Libraries (Applied Biosystems now part
of Thermo Fisher Scientific) according to the manufacturer’s
instructions. Purification was performed on 10% TBE-Urea
gels stained with Sybr Gold nucleic acid gel stain (both
from Invitrogen now part of Thermo Fisher Scientific). Final
purification was performed using PureLink PCR Micro Kit
(Invitrogen). Final libraries were quality checked using High
Sense DNA kit on Bioanalyzer (all from Agilent, Santa Clara,
CA). Concentration of each library was determined using the
SOLID Library TaqMan Quantitation Kit (Life Technologies
now part of Thermo Fisher Scientific). Each library was clonally
amplified on SOLiD P1 DNA Beads by emulsion PCR (ePCR).
Emulsions were broken with butanol, and ePCR beads enriched
for template-positive beads by hybridization with magnetic
enrichment beads. Template-enriched beads were extended at
the 3′ end in the presence of terminal transferase and 3′ bead
linker. Beads with the clonally amplified DNA were deposited
onto SOLiD sequencing slide and sequenced on SOLiD 5500
Instrument using the 50-base sequencing chemistry.
Bioinformatic Analysis Raw data quality assessment, read
trimming read mapping and miRNA expression profiling were
carried out in CLCGenomicsWorkbench tool version 8.0.2 (CLC
Bio now part of Qiagen, Venlo, Netherlands) using annotated
Mus musculus miRNA sequences according to the miRBase
release 21 as a mapping reference.
In vitro Experiments
Cell Cultures
6 × 104 cell/ml passage 2 MSCs were plated in cell culture
dishes (1.5 × 104/cm2). After 24 h incubation, MSC cultures
were exposed to B16F1-derived exosomes (40µg/ml exosomal
proteins; 1.5 × 1011 exosomes) at every 24 h. Samples were
exposed to exosomes for 24, 48, 72, and 96 h and then harvested
in method-competent buffers.
Visualization of Labeled Exosome Internalization in
MSCs
To examine the uptake of exosomes by MSCs, cells were plated
to black 24-well Visiplates (1 × 104 cells/well) and incubated for
24 h. The exosomes were labeled with Dil dye (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate, PromoKine,
Heidelberg, Germany) and the MSC cultures were labeled
with DiO dye (3,3′-dioctadecyloxacarbo-cyanine perchlorate,
PromoKine) according to the manufacturer’s instructions. Dil-
labeled exosomes were washed in DPBS by ultracentrifugation
(at 150,000 g for 1 h at 4◦C). Forty micrograms per milliliter
DiL-labeled exosomes were added to DiO-labeled MSC cultures
and the exosome uptake was followed for 24 h in the
Celldiscoverer 7 automated live cell imaging system (Zeiss,
Oberkochen, Germany). After 24 h, the cells were fixed with 4%
paraformaldehyde solution and a nucleus staining was performed
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using DAPI (Life Technologies now part of Thermo Fisher
Scientific). Then, 5 image z-stacks were acquired for both
channels by Operetta High Content Screening System (Perkin
Elmer, Waltham, MA). The stacks were maximum intensity
projected and then analyzed automatically using a customized
version of CellProfiler (18). Nuclei were detected with Otsu-
adaptive threshold combined with diameter based filtering, then
cytoplasms were identified with propagation method seeded
from the nuclei and using the exosome channel. Exosomes were
located with a customized version of A-trous wavelet transform
based spot detection (19). Several wavelet levels were used to
ensure the detection of exosomes with various size and then the
overlaps were removed based on circularity measures. Finally,
the exosome numbers per cell were identified using MATLAB
programming, the diagrams were created in Microsoft Excel.
Cell Proliferation
After 72 h incubation, exosome-exposed and control MSC
cultures were dissociated with trypsin from the culture surface.
Cells were washed in medium and counted in a Bürker chamber
and a cell counter (Bio-Rad, TC10 Automated Cell Counter).
Detection of Apoptosis
Exosome-exposed MSCs and control cells were treated with
100 ng/ml mouse TNFα (R&D Systems). After 24 h incubation,
cell death was determined by the Annexin V Apoptosis Detection
Kit with PI (Biolegend, San Diego, CA) according to the
manufacturer’s recommendations. Samples were measured by
FACS Calibur flow cytometer (BD Biosciences), data were
analyzed by Flowing Software (Cell Imaging Core, Turku Center
for Biotechnology, Finland) where percent of positive cells was
determined by relative fluorescence intensity and the results were
expressed as mean of percentage of positive cells (%) ±SD. Cells
that are annexin-V/PI double positive show the sign of late
apoptosis, while cells that are annexin-V positive and PI negative
indicate early apoptosis. Annexin-V negative and PI positive
cells are necrotic, viable cells are both annexin-V, and propidium
iodide (PI) negative.
RNA Preparation, Melan-A, and Mitf Quantitative
Real-Time PCR (QRT-PCR)
Total RNA of biological samples was purified using the Quick-
RNA MiniPrep isolation kit of #R1054S (Zymo Research Irvine,
CA). All the preparation steps were carried out according the
manufacturer’s instructions. RNA samples were stored at −80◦C
in the presence 30U of Prime RNAse inhibitor (Fermentas, part
of Thermo Fisher Scientific) for further analysis. The quantity
of isolated RNA samples was checked by spectrophotometry
(NanoDrop 3.1.0, Rockland, DE).
QRT-PCR was performed on a RotorGene 3000 instrument
(Corbett Research, Sydney, Australia) with gene-specific primers
and SybrGreen protocol to monitor gene expression. One
microgram of total RNA was reverse transcribed with random
primers using the High-Capacity cDNA Archive Kit (Applied
Biosystems) according to the manufacturer’s instructions in
final volume of 30 µl. The temperature profile of the reverse
transcription was the following: 10min at room temperature, 2 h
at 37◦C, 5min on ice, and finally 10min at 75◦C for enzyme
inactivation. These steps were carried out in a Thermal Cycler
machine (MJ Research, Marshall Scientific, Hampton, NH). After
dilution with 30 µl of water, 1 µl of the diluted reaction mix
was used as template in the QRT-PCR. Reactions were done
with FastStart SYBR Green Master mix (Roche) according to
the manufacturer’s instructions at a final primer concentration
of 250 nM under the following conditions: 15min at 95◦C, 40
cycles of 95◦C for 15 s, 60◦C for 25 s, and 72◦C for 25 s. The
fluorescence intensity of SybrGreen dye was detected after each
amplification step. Melting temperature analysis was done after
each reaction to check the quality of the products. Primers
were designed using the online Roche Universal Probe Library
Assay Design Center. The quality of the primers was verified by
MS analysis provided by Bioneer (Daejeon, Republic of Korea).
Relative expression ratios were calculated as normalized ratios
to MmRpl27 (Mus musculus ribosomal protein L27) gene. Non-
template control sample was used for each PCR run to check the
primer-dimer formation. The final relative gene expression ratios
were calculated as delta-delta Ct values. Information about the
genes and the primers is collected in Table S1.
RNA Isolation, Reverse Transcription, and TaqMan
Panel
RNAs were isolated from MSC cells with Qiagen RNeasy mini
kit (Qiagen) based on the manufacturer’s instruction. RNA
concentrations were measured by NanoDrop spectrophotometer
(NanoDrop). cDNAs were reverse transcribed with TaqMan
Reverse Transcription Reagents (Thermo Fisher Scientific)
following the manufacturer’s instruction. For the TaqMan QRT-
PCR panel, cDNA mixture of three parallel samples was
used in case of each condition: control, 6, 24, and 72 h
exosome treatment applied on MSC cells derived from four
mice. Eighty nanogram cDNA and TaqMan Gene Expression
Master Mix (Thermo Fisher Scientific) were used for the
qPCR experiment. Expression of the examined 44 genes was
calculated by 11Ct method and normalized to the average
Ct values of 4 internal controls (PPIA, 18S RNA, ACTB,
and GAPDH).
PD-1 Detection
PD-1 detection by Western blotting
The cells were washed three times in PBS, then were lysed
in TENT Buffer (50mM Tris-HCl, 2mM EDTA, 150mM
NaCl, 1% TritonX-100, completed with 1x protease inhibitor
cocktail (Roche). Protein samples were separated and blotted as
described above.
For PD-1 protein level detection, anti-PD-1 (clone: RMO1-
14, Biolegend) antibody was used in 1:1,000 dilution. Anti-rat
horseradish peroxidase (HRP)-conjugated secondary antibody
(R&D Systems) was used in 1:500 dilution.
PD-1 detection by Immunofluorescence microscopy
MSC cultures were fixed with 4% paraformaldehyde for 10min,
and blocked in PBS buffer containing 5% BSA (Sigma-Aldrich)
for 60min at room temperature. After blocking, cells were
incubated with primary antibody in DPBS buffer containing
Frontiers in Immunology | www.frontiersin.org 5 October 2019 | Volume 10 | Article 2459
Gyukity-Sebestyén et al. Melanoma-Derived Exosomes Induce PD-1
1.2% BSA overnight at 4◦C. As primary antibodies, 1:200 anti-
PD-1 (clone: RMO1-14, Biolegend,) and 1:200 anti-MLANA
(Byorbit) were used. After incubation, cells were washed three
times in PBS, and incubated for 1 h at room temperature with
1:100 Alexa Fluor 647-conjugated anti-rat antibody (Jackson
ImmunoResearch Laboratories, Baltimore, PA) or 1:500 Alexa
Fluor 555-conjugated anti-rabbit antibody (Thermo Fisher
Scientific). Tubulin was stained with 1:500 Alexa Fluor 488-
conjugated anti-tubulin-α antibody (clone: 10D8, Biolegend).
Nucleus staining was performed using DAPI (Life Technologies).
Slides were washed three times with DPBS between each step.
Images were obtained at 60x magnification using an Olympus
confocal laser scanning microscope.
PD-1 detection by STORM super-resolution imaging
All dSTORM super-resolution experiments were performed on
a custom-made inverted microscope based on a Nikon Eclipse
Ti-E frame. After being conditioned (through spatial filtering via
fiber coupling and beam expansion) the applied laser beams were
focused into the back focal plane of the microscope objective
(Nikon CFI Apo 100x, NA= 1.49), which produced a collimated
beam on the sample. The angle of illumination was set via a
tilting mirror mounted into a motorized gimbal holder and
placed into the conjugate plane of the sample. All the dSTORM
images were captured under EPI illumination at an excitation
wavelength of 647 nm (Nikon: 647 nm, 300 mW). The laser
power, controlled via an acousto-optic tunable filter (AOTF), was
set to 4 kW/cm2 on the sample plane. An additional laser (Nichia,
Anan, Tokushima, Japan, 405 nm, 60 mW) was used for both
reactivation and reference measurements. Images were captured
by an Andor iXon3 897 BV EMCCD digital camera (512 × 512
pixels with pixel size of 16µm). The size of the illuminated region
of the sample was matched to the size of the detector, which
determined the field of view (FOV= 80× 80µm2). Frame stacks
for dSTORM super-resolution imaging were typically captured
at a reduced image size (crop mode), when only the central
128 × 128 pixel region was selected. A fluorescence filter set
(Semrock, Rochester, NY, LF405/488/561/635-A-000) was used
to select and separate the excitation and emission lights in
the microscope. Additional emission filters (Semrock, BLP01-
647R-25) were used in the detection path to further clean the
fluorescent light spectrally for the reduction of spectral crosstalk.
During the measurements, the perfect focus system of the
microscope was used to keep the sample in focus with a precision
of <30 nm. The storage buffer on the sample was replaced with
a special switching buffer (20). Typically, 10,000 frames were
captured with an exposure time of 30ms. Reference images with
full size FOV were captured at low intensity when the majority of
fluorescent molecules were still active and the overall structure of
the labeled sample could be visualized.
The captured and stored image stacks were evaluated
and analyzed by rainSTORM localization software (21). The
individual images of single molecules were fitted with a Gaussian
point spread function and their center positions were associated
with the position of the fluorescent molecule. Localizations were
filtered via their intensity, ellipticity and standard deviation
values. Localizations with precisions of <45 nm were only used
to form the final image. The estimated mean precision of the
accepted localizations was 19 nm. Mechanical drift introduced by
either the mechanical movement of the sample or thermal effects
was analyzed and reduced by means of a blind drift correction
algorithm. Spatial coordinates of the localized molecules were
stored and the final super-resolved image was visualized. The
multicolor merged images were generated by ImageJ software.
In vivo Experiments
Mouse Model
B16F1melanoma cells were administrated intravenously (1× 105
cell/100 µl) to 6–8 week old female C57BL/6N mice (Charles
River Laboratories). One week later, tumor bearing mice were
randomized and divided into 3 groups (n = 10/group). Mice
were injected intravenously with control buffer (100µl), exosome
exposed MSCs (1 × 105 cell/100 µl) or exosomes (40 µg/100
µl) 7, 8, 9, 10, 11 days after the tumor injection (Table S2).
One week after the first MSC administration, 3 animals/group
were euthanized, their lungs were removed, photographed and
stored at −80◦C for further protein, mRNA and histological
analyses. The remained mice were observed for 10 more days.
At the end point, the animals were euthanized, and the tumor
metastases were investigated not only in their lung, but also
in their entire body and removed for histological analysis.
Experiments were repeated 3 times. All animal experiments
were performed in accordance with national (1998. XXVIII;
40/2013) and European (2010/63/EU) animal ethics guidelines.
The experimental protocols were approved by the Animal
Experimentation and Ethics Committee of the Biological
Research Centre of the Hungarian Academy of Sciences and the
Hungarian National Animal Experimentation and Ethics Board
(clearance number: XVI./03521/2011 and XV./78/2018).
Tumor Coverage
Tumor coverage of lungs was determined by the analysis of
acquired images using the ImageJ software. The area of tumors
and the healthy regions was measured and the mean percentage,
SD, and p values were calculated in Microsoft Excel.
Quantification of Metastases Associated Vessel
Diameters
From native animal lungs 4µm criostat sections were made on
silanized slides, than fixed and retrieved by Fix and Perm A-B
solution (Thermo Fisher Scientific, USA) for 20min. Sections
were counterstained by conventional hematoxilin for 30min
than washed in tap water and coverslipped. Sections were
digitalized by automatic slide-scanner (3DHistech, Hungary),
using the software 3DHISTECHPannoramic Viewer (3DHistech,
Hungary). Strict tumor border was carefully marked then vessel
diameters were measured.
Cytokine and Chemokine Array
Lung samples were lysed in NP40 cell lysis buffer (Thermo
Fisher Scientific, USA) and protein content was measured by the
Pierce BCA Protein Assay kit (Thermo Fisher Scientific, USA).
Expression levels of different cytokines in pooled lung specimens
were determined using Mouse Cytokine Array Panel A (R&D
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Systems, Cat. no. ARY006), according to the manufacturer’s
instructions. Immunoreactive signals were detected by using LI-
CORODYSSEY Fc (Dual-mode imaging system) imager followed
by analysis with Image Studio Lite v5.2.
Custom TaqMan Array Panels
QRT-PCR was performed on an ABI Prism 7000 sequence
detection system (Applied Biosystems) using specific pre-
designed customized 96-well TaqMan Array oncogene panels
(Thermo Fisher Scientific) containing 44 specifically selected
primers and probes according to extensive literature work.
Total RNA was isolated using TRIzol (Thermo Fisher
Scientific), DNase treatment was performed according
to the manufacturer’s protocol, and then total RNA was
transcribed into cDNA using High Capacity cDNA Kit
(Thermo Fisher Scientific). PCR amplification was performed
using TaqMan primers and probes and thermal cycle
conditions were set as follows: 2min at 50◦C, 10min
at 95◦C, and 40 cycles of 15 s at 95◦C and 1min at
60◦C. As internal control transcripts of ACTB (Assay ID:
Mm00607939_s1), GAPDH (Assay ID: Mm99999915_g1),
and PPIA (Assay ID: Mm02342430_g1) were determined.
The amount of the transcripts was normalized to those of
the housekeeping genes using the 1Ct method. Finally the
results were normalized to the expression of the vehicle
control (11Ct method).
For relationship discovery Hierarchical Cluster Analysis
was performed by R software. In detail, the “bottom up”
agglomerative hierarchical clustering strategy was used and
results represented in a tree-based dendrogram [For refer the R
software: (22)].
Network Representation by Ingenuity Pathway
Analysis
According to literature data, we established a protein network
from the in vivo overexpressed genes. A custom graphical
representation of this network was generated using the Path
Explorer tool of the IPA Path Designer. Genes are represented
as red nodes, using various shapes that represent the functional
class of the gene product. In a few cases proteins are
substituted with the complex, which they are involved in.
To identify the potential exosomal factors, which can induce
the activation of the network, a list was generated from the
exosomal proteins detected by LC-MS/MS and the exosomal
miRNAs identified by SOLiD sequencing. The Grow tool
in the IPA Path Designer revealed significant interactions
between the network and the generated list (the interacting
exosomal factors are listed in gray boxes and the types of
relationships are indicated in parentheses). During construction
in the IPA, the significance level was set to “experimentally
observed” data to avoid the representation of predicted,
unproven interactions.
FIGURE 1 | Characterization of B16F1 melanoma cell culture-derived exosomes. (A) Scanning electron micrograph of melanoma exosomes. (B) Atomic force
microscopy images of exosomes. Left and middle pictures represent the shape and surface topography of vesicles, right graph represents height profile. (C) Western
blot analysis of common exosome markers (CD9, CD63, CD81, and HSP70). (D,E) Top 5 molecular and cellular functions identified by Ingenuity Pathway Analysis of
exosomal proteins and miRNAs.
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TABLE 1 | List of exosomal proteins identified by LC-MS/MS.
ID Symbol Entrez gene name
P97857 ADAMTS1 ADAM metallopeptidase with
thrombospondin type 1 motif 1
Q3TNX8 ADAMTS4 ADAM metallopeptidase with
thrombospondin type 1 motif 4
Q640N1 AEBP1 AE binding protein 1
P05064 ALDOA Aldolase, fructose-bisphosphate A
P97429 ANXA4 Annexin A4
P48036 ANXA5 Annexin A5
P08226 APOE Apolipoprotein E
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1
P97370 ATP1B3 ATPase Na+/K+ transporting subunit beta 3
Q1XID4 ATP6AP2 ATPase H+ transporting accessory protein 2
Q9JL18 BACE2 Beta-site APP-cleaving enzyme 2
O55107 BSG Basigin (Ok blood group)
Q8R2Q8 Bst2 Bone marrow stromal cell antigen 2
Q9WVT6 CA14 Carbonic anhydrase 14
P41731 CD63 CD63 molecule
P35762 CD81 CD81 molecule
P10605 CTSB Cathepsin B
P18242 CTSD Cathepsin D
P29812 DCT Dopachrome tautomerase
P57776 EEF1D Eukaryotic translation elongation factor 1
delta
Q3UAM9 ENG Endoglin
P17182 ENO1 Enolase 1
P19096 FASN Fatty acid synthase
P30416 FKBP4 FK506 binding protein 4
P11276 FN1 Fibronectin 1
P09528 FTH1 Ferritin heavy chain 1
P16858 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
P08752 GNAI2 G protein subunit alpha i2
Q3TAV1 GPNMB Glycoprotein nmb
P19157 GSTP1 Glutathione S-transferase pi 1
P11499 HSP90AB1 Heat shock protein 90 alpha family class B
member 1
B1B0C7 HSPG2 Heparan sulfate proteoglycan 2
Q9CQW9 IFITM3 Interferon induced transmembrane protein 3
G3UYZ1 IGSF8 Immunoglobulin superfamily member 8
Q91VK4 ITM2C Integral membrane protein 2C
P02468 LAMC1 Laminin subunit gamma 1
Q60961 LAPTM4A Lysosomal protein transmembrane 4 alpha
P35951 LDLR Low density lipoprotein receptor
Q07797 LGALS3BP Galectin 3 binding protein
Q3U2W5 LGALS8 Galectin 8
P16056 MET MET proto-oncogene, receptor tyrosine
kinase
P21956 MFGE8 Milk fat globule-EGF factor 8 protein
Q2TA50 MLANA Melan-A
Q6NVG5 MREG Melanoregulin
Q9EPX2 PAPLN Papilin, proteoglycan like sulfated
glycoprotein
(Continued)
TABLE 1 | Continued
ID Symbol Entrez gene name
Q3UIP2 PCOLCE Procollagen C-endopeptidase enhancer
Q811J2 LOC72520 LOC72520 protein
Q80Y09 PDCD6IP Programmed cell death 6 interacting protein
P62962 PFN1 Profilin 1
P09411 PGK1 Phosphoglycerate kinase 1
P52480 PKM Pyruvate kinase, muscle
Q9CZB2 PMEL Premelanosome protein
P17742 PPIA Peptidylprolyl isomerase A
P35700 PRDX1 Peroxiredoxin 1
Q61171 PRDX2 Peroxiredoxin 2
Q543S0 PRELP Proline and arginine rich end leucine rich
repeat protein
P53994 RAB2A RAB2A, member RAS oncogene family
Q8CCG5 RALB RAS like proto-oncogene B
O89086 RBM3 RNA binding motif (RNP1, RRM) protein 3
P35980 RPL18 Ribosomal protein L18
Q3U5P4 SCPEP1 Serine carboxypeptidase 1
O08992 SDCBP Syndecan binding protein
Q0VGP2 SEMA3B Semaphorin 3B
P32261 SERPINC1 Serpin family C member 1
P10852 SLC3A2 Solute carrier family 3 member 2
Q3UQM7 SLC7A5 Solute carrier family 7 member 5
O09044 SNAP23 Synaptosome associated protein 23
Q64337 SQSTM1 Sequestosome 1
Q8CI59 STEAP3 STEAP3 metalloreductase
Q3TDG9 STX12 Syntaxin 12
O70439 STX7 Syntaxin 7
P40749 SYT4 Synaptotagmin 4
O88968 TCN2 Transcobalamin 2
Q542D9 TFRC Transferrin receptor
P39876 TIMP3 TIMP metallopeptidase inhibitor 3
Q4FJX7 TINAGL1 Tubulointerstitial nephritis antigen like 1
Q9DCS1 TMEM176A Transmembrane protein 176A
Q9R1Q6 TMEM176B Transmembrane protein 176B
Q9CZX7 TMEM55A Transmembrane protein 55A
Q9QY73 TMEM59 Transmembrane protein 59
O88746 TOM1 Target of myb1 membrane trafficking protein
O89023 TPP1 tripeptidyl peptidase 1
Q3UCW0 TSG101 Tumor susceptibility 101
Q4FJW7 TSPAN4 Tetraspanin 4
Q8BJU2 TSPAN9 Tetraspanin 9
P11344 TYR Tyrosinase
P07147 TYRP1 Tyrosinase related protein 1
O70404 VAMP8 Vesicle associated membrane protein 8
Q8R0J7 VPS37B VPS37B, ESCRT-I subunit
Q8R105 VPS37C VPS37C, ESCRT-I subunit
O88384 VTI1B Vesicle transport through interaction with
t-SNAREs 1B
A8DUQ1 HBBT1 Beta-globin
P70356 MELA Gag-pol poliprotein
P70355 MELA Envelope protein
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Statistical Analysis
All of the data are presented as the mean ± SD or SEM and
represent minimum of three independent experiments. Statistical
parameters including statistical analysis, statistical significance,
and n value are reported in the figure legends. For in vivo
experiments n = number of animals. For statistical comparison,
we performed two-tailed Student’s t-test. A value of p < 0.05
was considered significant [represented as ∗p < 0.05, not
significant (n.s.)].
RESULTS
Isolated Vesicles Show Exosomal
Properties
First, we isolated extracellular vesicles from B16F1 mouse
melanoma cells. As it was shown by SEM and AFM
(Figures 1A,B), the isolated fraction indeed contained exosomes
as the particles were cap-shaped, and their size was within the
40–120 nm range. Then, presence of molecules (CD9, CD63,
CD81, and HSP70), characteristic for exosomes (4, 17) was
assessed by Western blotting (Figure 1C).
Exosomes were then subjected to large-scale analysis to
determine their protein and miRNA profiles. Whole proteome
analysis (using LC-MS/MS) and bioinformatics tools (used
to identify elements of the exosome’s proteomics spectrum
in the UniProt database, and to compare the findings with
entries of the ExoCarta database) revealed that 95 distinct
proteins were identified in melanoma exosomes (Table 1).
These proteins exhibited 86.3% overlap with molecules listed
as characteristic exosome protein markers in ExoCarta. Further,
miRNA sequencing (using SOLiD 5500xl technology) identified
168 known miRNA elements (Table 2) which, similarly to the
proteomics data, exhibited a large (93.5%) overlap withmolecules
listed as characteristic exosome miRNA markers in ExoCarta.
To uncover the functional significance of the proteomics and
miRNA sequencing data, IPA was employed. This analysis has
shown that the identified proteins most probably participated
in cellular and molecular processes such as “Cell Death and
Survival,” “Cellular Movement,” “Cell-to-Cell Signaling and
Interaction,” “Cellular Growth and Proliferation,” and “Cell
Morphology” (Prange = 7.53 × 10−15-9.32 × 10−4 significance
range) (Figure 1D). Very similarly to these data, functions
of the identified miRNAs were suggested to be linked to
mechanisms of “Cellular Development,” “Cellular Growth and
Proliferation,” “Cellular Movement,” “Cell Cycle,” and “Cell
Death and Proliferation” (Prange = 1.25 × 10−12-4.88 × 10−2
significance range) (Figure 1E).
Tumor Exosome Exposure Resulted in
Oncogenic Reprogramming of MSCs
in vitro
Then, we investigated the effect of exosomes on biological
processes (e.g., proliferation, survival, malignant transformation,
etc.) of MSCs, which are generally considered as proper in vitro
models of tumor stroma (12). For these experiments, MSC
TABLE 2 | List of exosomal miRNAs identified by SOLiD 5500xl technology.
Symbol Seed regio ID
let-7a-3p UAUACAA mmu-let-7a-1-3p
mmu-let-7b-3p
mmu-let-7c-2-3p
mmu-let-7f-1-3p
let-7a-5p GAGGUAG mmu-let-7a-5p
mmu-let-7b-5p
mmu-let-7c-5p
mmu-let-7d-5p
mmu-let-7e-5p
mmu-let-7f-5p
mmu-let-7g-5p
mmu-mir-98-5p
let-7d-3p UAUACGA mmu-let-7d-3p
let-7i-3p UGCGCAA mmu-let-7i-3p
miR-100-5p ACCCGUA mmu-mir-99a-5p
mmu-mir-99b-5p
miR-101-3p ACAGUAC mmu-mir-101a-3p
miR-103-1-5p GCUUCUU mmu-mir-107-5p
miR-103-3p GCAGCAU mmu-mir-103-3p
mmu-mir-107-3p
miR-10a-5p ACCCUGU mmu-mir-10a-5p
mmu-mir-10b-5p
miR-1191a AGUCUUA mmu-mir-1191a
miR-1249-3p CGCCCUU mmu-mir-1249-3p
miR-125b-5p CCCUGAG mmu-mir-125a-5p
mmu-mir-125b-5p
mmu-mir-351-5p
miR-126a-5p AUUAUUA mmu-mir-126a-5p
miR-128-3p CACAGUG mmu-mir-128-3p
miR-129-1-3p AGCCCUU mmu-mir-129-1-3p
mmu-mir-129-2-3p
miR-129b-5p CUUUUUG mmu-mir-129b-5p
miR-130a-3p AGUGCAA mmu-mir-130a-3p
mmu-mir-130b-3p
mmu-mir-301a-3p
mmu-mir-301b-3p
miR-130a-5p CUCUUUU mmu-mir-130a-5p
miR-130b-5p CUCUUUC mmu-mir-130b-5p
miR-132-3p AACAGUC mmu-mir-132-3p
miR-132-5p ACCGUGG mmu-mir-132-5p
miR-135a-5p AUGGCUU mmu-mir-135a-5p
miR-138-5p GCUGGUG mmu-mir-138-5p
miR-139-5p CUACAGU mmu-mir-139-5p
miR-140-3p ACCACAG mmu-mir-140-3p
miR-140-5p AGUGGUU mmu-mir-140-5p
miR-142-3p GUAGUGU mmu-mir-142a-3p
miR-143-5p mmu-mir-143-5p
miR-144-3p ACAGUAU mmu-mir-144-3p
miR-144-5p GAUAUCA mmu-mir-144-5p
miR-145-5p UCCAGUU mmu-mir-145a-5p
(Continued)
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TABLE 2 | Continued
Symbol Seed regio ID
miR-146a-5p GAGAACU mmu-mir-146a-5p
miR-148a-3p CAGUGCA mmu-mir-148b-3p
miR-151-3p UAGACUG mmu-mir-151-3p
miR-15a-3p AGGCCAU mmu-mir-15a-3p
miR-15b-3p GAAUCAU mmu-mir-15b-3p
miR-16-2-3p CCAAUAU mmu-mir-16-2-3p
miR-16-5p AGCAGCA mmu-mir-15a-5p
mmu-mir-15b-5p
mmu-mir-16-5p
mmu-mir-195a-5p
mmu-mir-322-5p
mmu-mir-497a-5p
miR-17-3p CUGCAGU mmu-mir-17-3p
miR-17-5p AAAGUGC mmu-mir-106b-5p
mmu-mir-17-5p
mmu-mir-20a-5p
mmu-mir-93-5p
miR-181a-1-3p CCAUCGA mmu-mir-181a-1-3p
miR-181a-5p ACAUUCA mmu-mir-181a-5p
mmu-mir-181b-5p
mmu-mir-181c-5p
mmu-mir-181d-5p
miR-1827 GAGGCAG mmu-mir-709
miR-1839-3p GACCUAC mmu-mir-1839-3p
miR-185-5p GGAGAGA mmu-mir-185-5p
miR-186-5p AAAGAAU mmu-mir-186-5p
miR-187-3p CGUGUCU mmu-mir-187-3p
miR-188-3p UCCCACA mmu-mir-188-3p
miR-188-5p AUCCCUU mmu-mir-188-5p
miR-18a-5p AAGGUGC mmu-mir-18a-5p
miR-191-5p AACGGAA mmu-mir-191-5p
miR-193a-3p ACUGGCC mmu-mir-193a-3p
miR-1981-3p AUCUAAC mmu-mir-1981-3p
miR-199a-3p CAGUAGU mmu-mir-199a-3p
mmu-mir-199b-3p
miR-199a-5p CCAGUGU mmu-mir-199a-5p
mmu-mir-199b-5p
miR-19b-3p GUGCAAA mmu-mir-19a-3p
mmu-mir-19b-3p
miR-204-5p UCCCUUU mmu-mir-211-5p
miR-21-5p AGCUUAU mmu-mir-21a-5p
miR-210-3p UGUGCGU mmu-mir-210-3p
miR-210-5p GCCACUG mmu-mir-210-5p
miR-219a-5p GAUUGUC mmu-mir-219a-5p
miR-22-3p AGCUGCC mmu-mir-22-3p
miR-22-5p GUUCUUC mmu-mir-22-5p
miR-221-3p GCUACAU mmu-mir-222-3p
miR-223-3p GUCAGUU mmu-mir-223-3p
miR-224-5p AAGUCAC mmu-mir-224-5p
miR-23a-3p UCACAUU mmu-mir-23a-3p
mmu-mir-23b-3p
(Continued)
TABLE 2 | Continued
Symbol Seed regio ID
miR-24-1-5p UGCCUAC mmu-mir-24-2-5p
miR-24-3p GGCUCAG mmu-mir-24-3p
miR-26a-5p UCAAGUA mmu-mir-26a-5p
miR-26a-5p UCAAGUA mmu-mir-26a-5p
mmu-mir-26b-5p
miR-27a-3p UCACAGU mmu-mir-27a-3p
mmu-mir-27b-3p
miR-29a-5p CUGAUUU mmu-mir-29a-5p
miR-29b-1-5p CUGGUUU mmu-mir-29b-1-5p
miR-29b-3p AGCACCA mmu-mir-29a-3p
mmu-mir-29b-3p
mmu-mir-29c-3p
miR-3065-5p CAACAAA mmu-mir-3065-5p
miR-30c-5p GUAAACA mmu-mir-30a-5p
mmu-mir-30b-5p
mmu-mir-30c-5p
mmu-mir-30d-5p
mmu-mir-30e-5p
miR-31-3p GCUAUGC mmu-mir-31-3p
miR-31-5p GGCAAGA mmu-mir-31-5p
miR-3176 CUGGCCU mmu-mir-378d
miR-324-5p GCAUCCC mmu-mir-324-5p
miR-328-3p UGGCCCU mmu-mir-328-3p
miR-329-3p ACACACC mmu-mir-362-3p
miR-33-5p UGCAUUG mmu-mir-33-5p
miR-330-5p CUCUGGG mmu-mir-326-3p
miR-331-3p CCCCUGG mmu-mir-331-3p
miR-339-5p CCCUGUC mmu-mir-339-5p
miR-340-3p CCGUCUC mmu-mir-340-3p
miR-344a-5p CAGGCUC mmu-mir-484
miR-345-5p CUGACCC mmu-mir-345-5p
miR-3473b GGCUGGA mmu-mir-3473b
mmu-mir-3473e
miR-34a-5p GGCAGUG mmu-mir-34a-5p
mmu-mir-34b-5p
mmu-mir-34c-5p
miR-34c-3p AUCACUA mmu-mir-34b-3p
miR-350 UCACAAA mmu-mir-350-3p
miR-361-5p UAUCAGA mmu-mir-361-5p
miR-362-5p AUCCUUG mmu-mir-362-5p
miR-374b-5p UAUAAUA mmu-mir-374b-5p
miR-378a-3p CUGGACU mmu-mir-378a-3p
mmu-mir-378c
miR-378a-5p UCCUGAC mmu-mir-378a-5p
miR-3909 GUCCUCU mmu-mir-877-3p
miR-423-3p GCUCGGU mmu-mir-423-3p
miR-423-5p GAGGGGC mmu-mir-423-5p
miR-425-5p AUGACAC mmu-mir-425-5p
miR-451a AACCGUU mmu-mir-451a
miR-501-5p AUCCUUU mmu-mir-501-5p
miR-503-5p AGCAGCG mmu-mir-503-5p
(Continued)
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Symbol Seed regio ID
miR-532-5p AUGCCUU mmu-mir-532-5p
miR-542-3p GUGACAG mmu-mir-542-3p
miR-574-5p GAGUGUG mmu-mir-574-5p
miR-582-5p UACAGUU mmu-mir-582-5p
miR-652-3p AUGGCGC mmu-mir-652-3p
miR-670-5p UCCCUGA mmu-mir-670-5p
miR-700-5p AAGGCUC mmu-mir-700-5p
miR-744-3p UGUUGCC mmu-mir-744-3p
miR-744-5p mmu-mir-744-5p
miR-7a-5p GGAAGAC mmu-mir-7a-5p
miR-872-3p GAACUAU mmu-mir-872-3p
miR-872-5p AGGUUAC mmu-mir-872-5p
miR-9-5p CUUUGGU mmu-mir-9-5p
miR-92a-3p AUUGCAC mmu-mir-25-3p
mmu-mir-32-5p
mmu-mir-92a-3p
cultures were initiated frommouse abdominal adipose tissue (17)
and were subjected to melanoma exosome treatment.
First, we assessed whether exosomes were internalized by
MSCs. High-throughput microscopy showed that MSCs [labeled
green by the DiOC18(3) lipid dye] indeed took up exosomes
[labeled red by the DilC18(3) lipid dye] as early as 1–2 h after
application (Figure S1). Importantly, after 24 h, the majority of
MSCs were loaded by exosomes (Figures 2A,B). Indeed, image
analysis and statistical evaluation revealed a 91% internalization
efficacy. This suggests that functional alterations demonstrated
by this study were due to exosome-induced cell-population, and
not individual cell level effects.
Then, we determined whether the internalized exosomes
could induce a melanoma-like malignant transformation of the
MSCs. By employing two complementary cell-countingmethods,
we found that proliferation rate of the MSCs significantly
accelerated 72 h after exosome exposure (Figure 2C). By flow
cytometry, we also showed that the exosome-treated MSCs
exhibited a partial resistance to the cell death-inducing
effects of 100 ng/ml tumor necrosis factor-α (TNFα) as the
fraction of the dead cells was significantly decreased in these
cultures (Figure 2D).
Since the exosomes were isolated from melanoma cells, we
were then intrigued to uncover whether the above alterations
(which all argue for the malignant transformation of the
susceptible cells) also resulted in de novo appearance of
melanoma-specific features in the transformed MSCs. To answer
this question, expression of the melanoma-specific markers
MLANA and MITF were investigated. By QRT-PCR, we found
that mRNA transcript levels of both markers elevated markedly
in MSCs upon exosome treatment (Figure 2E and Figure S2),
albeit the kinetics of elevation of the two molecules were slightly
different. Moreover, in good accordance with the mRNA data,
immunofluorescence labeling showed that exosome exposure
markedly increased the expression ofMLANA at the protein level
as well (Figure 2F).
Next, we assessed whether the above effects of exosomes
inducing a malignant-like transformation of the MSCs was
accompanied by a cellular-molecular oncogenic reprogramming
of the target cells. Naïve MSCs were exposed to a standardized
volume of exosomes for various time intervals (to avoid the
experimental fluctuations, we collected pooled samples from
multiple independent in vitro experiments). Then, samples were
subjected to QRT-PCR analysis using a self-designed panel of 40
oncogenes and tumor suppressor genes which were previously
suggested to play a role in melanoma progression (Table 3).
As shown in Figure 3A, gene expression pattern of MSCs
exposed to melanoma exosomes, exhibited a clear oncogenic
dominance (compared to the non-exposed cells). This was
verified by statistical analysis of themean relative gene expression
levels of all molecules investigated. Statistically higher values
were obtained in the case of exosome-treated cells (p = 1.9 ×
10−5, p = 0.031 and p = 2.3 × 10−8 for the 6, 24, and 72 h time
points, respectively).
As mentioned above, Kleffel et al. has recently shown
that melanoma cell subpopulations which overexpress PD-1,
quite intriguingly exhibit remarkably increased invasiveness
and aggressive growth properties (15). However, the authors
did not define the factor(s) which induced the above PD-1
overexpression. Since the above finding strongly suggested an
“MSC re-education” capacity of melanoma exosomes to induce
malignant-like behavior, we next assessed the expression of PD-1
in MSC cultures.
As expected, only insignificant PD-1 expression (both at the
mRNA and protein levels) could be identified in control, non-
treated MSCs. In contrast, a marked, significant, and time-
dependent elevation of PD-1 expression was detected upon
exosome treatment by QRT-PCR (Figure 3B), Western blot and
an immunocytochemical analysis (Figures 3C,D). Further, by
employing super-resolution microscopy, we were able to identify
a dramatic upregulation of PD-1 at the single molecular level in
exosome-treated MSCs (Figure 3E).
Importantly, since proteomics analysis did not identify the
presence of PD-1 in exosomes, these data suggest that the high
PD-1 protein content in exosome-exposed MSCs was a result
of de novo induction and not of exosome-mediated molecular
transfer. Our findings therefore suggest that melanoma exosome-
mediated “re-education” of the cells resulted in a novel MSC
population which could be identified as MSCPD-1+.
B16F1 Exosomes Augment in vivo
Tumorigenesis and Tumor Progression
After presenting evidence for the in vitro tumorigenic induction
potential of exosomes on cultured MSCs, we hypothesized
that this phenomenon could be identified in vivo as well. To
probe this assumption, we employed the well-known animal
model, routinely used in our laboratories (46), in which
tumors, developed mostly in the lungs, are induced in mice
by intravenous administration of mouse B16F1 melanoma cells
(to the tail vein). Then, tumor-bearing mice received buffer,
or exosomes isolated from the same B16F1 melanoma cells, or
exosome-induced MSCPD-1+ cells.
Notably, the exosome-related groups (i.e., exosome,
MSCPD-1+) were characterized by a markedly increased
size of tumor-covered lung tissues (the increase proved to be
significant in the MSCPD-1+ group) (Figure 4A). Of further
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FIGURE 2 | Internalized melanoma exosomes induce malignant transformation of the recipient MSCs. (A) Fluorescent images of exosome uptake by MSCs. DiO
(green lipid dye)-labeled cells were exposed to Dil (red lipid dye)-labeled exosomes for 24 h and fixed in 4% PFA. Control cells were treated in the same manner without
exosomes. Pictures were acquired by an Operetta high content screening system (Perkin Elmer). Lower two images represent an experiment, where nuclei were
counterstained with DAPI. Exosomes were detected with a customized version of A-trous wavelet transform, and were highlighted with yellow. (B) Quantitative analysis
of exosome uptake. The graph shows the number of detected exosomes (Y axis) in each cell (X axis) in three exosome-exposed (24 h) and three control cell cultures
(ctrl). (C) Cell proliferation assay of exosome-exposed MSCs. Cells were plated at 1 × 104 cell/cm2 density in control and exosome-exposed cultures, and 72 h after
the exosome treatment, the cell number was determined by manual counting and by an automated cell counter. Both methods showed a significantly increased cell
proliferation of exosome-treated cells. Results are presented as mean ± SD (n = 3). (D) Apoptosis analysis of exosome-exposed MSCs by flow cytometry.
Exosome-pre-exposed cells were treated by 100 ng/ml TNFα for 24 h, stained with Annexin V-FITC and propidium iodide. They were analyzed by flow cytometry both
in the case of the TNFα-treated and the untreated control cell cultures. The graph represents the percentage of early apoptotic, late apoptotic and necrotic cells. Both
TNFα-induced total cell death (Σ ) and necrosis were significantly lower (Σp = 0.03 and p = 0.02, respectively) in exosome-pretreated cell cultures compared to the
corresponding control cells. Results are presented as mean + SD (n = 3). (E) QRT-PCR analysis of Mlana and Mitf in MSC cultures treated by exosomes in every 24 h
indicated by arrows in the graph. The expression of both mRNAs increased after exosome exposure, but they showed different kinetics. (F) Fluorescent
immunocytochemistry of MLANA in exosome-exposed MSC cultures using a primary rabbit antibody to MLANA and a secondary AlexaFluor555-conjugated antibody
to rabbit IgG (red). α-tubulin network of cells was directly labeled by an AlexaFluor488-conjugated antibody (green) and the nuclei were stained with DAPI (blue).
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TABLE 3 | List of genes investigated by a self-designed oncopanel.
Gene Protein Function References
Alcam ALCAM (CD166) Activated leukocyte cell
adhesion molecule
Plays an important role in human malignant melanoma progression and
formation of locoregional and distant metastases
(23)
Bmi1 BMI1 B cell-specific Moloney murine leukemia virus
integration site 1
Induces an invasive signature in melanoma that promotes metastasis and
chemoresistance
(24)
Cd44 CD44 Is a CD44s interaction with HA plays a crucial role in cell invasiveness (25)
Eng ENG Endoglin (CD105) Has a crucial role in angiogenesis, important protein for tumor growth, survival,
and metastasis of cancer cells to other locations in the body
(26)
Flot2 FLOT1 Flotillin-2 Is associated with melanoma progression (27)
Itga2 ITGA2 Integrin alpha2 Is associated with increased risk of melanoma (28)
Itga4 ITGA4 Integrin alpha 4 α4β1 integrin plays an important role in metastasis of malignant melanoma (28)
Itga6 ITGA6 Integrin alpha 6 α6β1 integrin as a laminin receptor expression is associated with invasive
potential in a highly metastatic melanoma cell line
(28)
Itgb1 ITGB1 Integrin beta-1 (CD29) α4β1 integrin plays an important role in metastasis of malignant melanoma (28)
Kit KIT (CD117) Mast/stem cell growth factor receptor
(SCFR)
c-Kit signaling activates the MAPK and PI3K signaling cascades (29)
Muc1 MUC1 Mucin1 cell surface associated Promotes melanoma migration through the Akt signaling pathway (29)
Pecam1 PECAM1 Platelet endothelial cell adhesion
molecule (CD31)
Can play multiple roles in diverse processes related to melanoma development,
dormancy, migration/invasion, and angiogenesis
(30)
Prom1 Prominin-1 (CD133) Is a melanoma stem cell marker (31)
Thy CD90 Is a cell adhesion molecule. Melanoma cells use Thy-1 on endothelial cells for
metastasis formation
(32)
Cdc42 CDC42 Cell division control protein 42 homolog Is vital for the transforming Ras signal emanating from endomembranes (33)
Tiam1 TIAM1 T-cell lymphoma invasion and metastasis 1 Has crucial roles in regulation of the actin cytoskeleton, cell migration, cell cycle
progression, gene transcription, and cell adhesion
(34)
Bcl2 BCL-2 B-cell lymphoma 2 Plays a pivotal role in the regulation of molecules associated with the migratory
and invasive phenotype, contributing, in cooperation to hypoxia, to tumor
progression
(29)
Bax BAX Bcl-2-associated X protein Plays a crucial role in apoptotic cell death induced, the Bax/Bcl-2 ratio
determines the susceptibility of melanoma cells
(35)
Casp9 CASP9 Caspase-9 Is linked to the mitochondrial death pathway (35)
Casp8 CASP8 Caspase-8 Plays a central role in the execution-phase of cell apoptosis (36)
Cdk4 CDK4 Cyclin-dependent kinase 4 Promotes cell-cycle progression and inhibit both cell senescence and apoptosis (29)
Elk1 ELK1 ETS domain-containing protein Elk-1 Is a member of ETS oncogene family, transcription activator (37)
Ets1 ETS1 E26 transformation-specific Is required for migration in cell lines with an active RAS/ERK signaling pathway (29)
Hgf HGF Hepatocyte growth factor Can activate the MAP-kinase pathway, which is upregulated in the majority of
melanoma, through the proto-oncogene c-MET
(38)
Jak2 JAK2 Janus kinase 2 Is an activator of transcription (STAT) pathway is thought to play a central role in
melanoma cell biology
(39)
Met MET Hepatocyte growth factor receptor Induces several biological responses that collectively give rise to a program
known as invasive growth
(40)
Myb MYB transcriptional activator Myb Is a transcription factor. Among other genes, MYB regulates the transcription of
the Kit, Bcl2, Ets-2, and N-Ras
(41)
Nras NRAS Neuroblastoma RAS viral oncogene homolog Recruits and stimulates a number of intracellular signaling pathways including
the Raf/MEK/ERK mitogen activated protein kinase (MAPK) pathway, the
PI3K/AKT pathway
(29)
Stat3 STAT3 Signal transducer and activator of transcription 3 Promotes transcription of many genes that involve in melanoma metastasis (42)
Kitl KIT-ligand Stem cell factor (CD117) Is a cytokine that binds to the c-KIT receptor. This cytokine plays an important
role in melanogenesis
(29)
Rb1 RB1 Retinoblastoma 1 protein Is a tumor suppressor protein that is dysfunctional in several major cancers (43)
Pik3ca PI3K Phosphatidylinositide 3-kinases Is a PI3K/AKT pathway play a pivotal role in tumor development, growth, and
metastasis of melanoma
(29)
Raf1 RAF1 Proto-oncogene serine/threonine-protein kinase Is a crucial regulators of the ERK MAP kinase signaling cascade (44)
(Continued)
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TABLE 3 | Continued
Gene Protein Function References
Mtor mTOR Serine/threonine-protein kinase Mechanistic target of rapamycin, is a serine/threonine protein kinase that
regulates cell growth, cell proliferation, cell motility, cell survival
(29)
Akt1 AKT Protein kinase B Plays a key role in multiple cellular processes such as glucose metabolism,
apoptosis, cell proliferation, transcription, and cell migration
(29)
Map2k1 MEK1 Dual specificity mitogen-activated protein kinase
kinase 1
Is an essential component of the MAP kinase signal transduction pathway, this
kinase is involved in many cellular processes such as proliferation, differentiation,
transcription regulation, and development
(29)
Map2k2 MEK2 Dual specificity mitogen-activated protein kinase
kinase 2
Plays a critical role in mitogen growth factor signal transduction. It
phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3
(29)
Mapk3 ERK1 Extracellular-signal-regulated kinases Ras-Erk1/2 is a key regulator pathway in melanoma cell proliferation (29)
Mapk1 ERK2 Mitogen-activated protein kinase 1 Ras-Erk1/2 is a key regulator pathway in melanoma cell proliferation (29)
Rac1 RAC1 Ras-related C3 botulinum toxin substrate 1 Functions in multiple signaling pathways are leading to cell adhesion, migration,
proliferation, and transformation
(45)
importance, we also found that in both exosome-related groups,
the numbers of distant metastases were significantly elevated
when compared to the control (Figure 4B), and diameter of
metastases associated blood vessels significantly increased in
exosome and MSCPD-1+ injected groups of tumor bearing mice
(Figure S3). Using of cytokine and chemokine arrays, tumor
supportive cytokine and chemokine levels were elevated in
exosome related groups (Figure S4). As we have seen during our
previous studies (46), these metastases were mostly localized to
the ovaries and kidneys (and very rarely to the lymph nodes)
of control tumor-bearing animals. However, besides these sites,
the presence of exosomes resulted in frequent metastases in the
lymph nodes and, as a new location, in the liver. Interestingly, in
MSCPD-1+ treated mice, exosome-transformed MSCs could be
identified in the para-aortic lymph nodes by FISH (Figure 4C)
verifying the successful in vivo adherence of MSCPD-1+ cells.
Lung tissues of the different groups were then subjected to in-
depth expressional profiling 14 days after injection of exosomes
or MSCPD-1+ cells. Namely, QRT-PCR analysis was performed
using a self-designed panel of 40 genes; besides housekeeping
genes, we assessed expression of (i) proto-oncogenes; (ii)
genes reportedly involved in malignant transformation; and/or
(iii) genes found to be involved in melanoma development
and progression.
Hierarchical cluster analysis (HCA) of the gene expression
patterns clearly showed a robust proto-oncogenic dominance
in lung samples of the exosome-related groups when compared
to the control tissues. Indeed, we identified significant de novo
induction of 26 and 23 genes: Alcam1, Eng, Flot2, Itga4,
Itga6, Kit, Pecam1, Prom1, Thy, Cdc42, Tiam1, Bcl2, Bax,
Casp9, Casp8, Ets1, Hgf, Jak2, Met, Myb, Map2k1, Map2k2,
Mapk1 in both group and Elk1, Rb1, Itga2 in the exosome
group. An additional six and three genes were identified
with at least 10-fold increase (Cd44, Itgb1, Muc1, Pik3ca,
Akt1, Rac1 in the exosome group and Cd44, Itgb1, Rac1
in the MSCPD-1+ group). Furthermore, six and eight genes
showed at least two-fold mRNA level elevations (Bmi1,
Cdk4, Stat3, Kitl, Raf1, Mtor and Bmi1, Muc1, Cdk4, Stat3,
Kitl, Pik3ca, Mtor, Akt1, respectively). Figure 4D presents a
heatmap of indicative data of overexpressed genes induced by
exosome exposure.
Furthermore, we showed that, besides the above genes,
expression of PD-1 was also significantly increased in both
exosome-related groups (Figure 4E). Notably, although mRNA
transcript level of PD-1 was close to two-fold in MSCPD-1+ lung
tissues in comparison to samples in the exosome group, the
difference was not significant (most probably due to the large
inter-animal variability and standard error).
We constructed a Venn-diagram (Figure 4F) to show all
possible logical connections between the various gene expression
patterns presented in Figure 4D. Importantly, according to
cluster analysis, we could not identify a single gene which
was missing from the exosome-related groups in comparison
to the control tumor-bearing mice. In other words, whereas
these exosome-related groups did exhibit gene expression profiles
which were characteristic only for them, such individual profiles
could not be detected in the control group.
Specifically, the following gene expression patterns
were defined:
• three genes (Elk1, Rb1, Igta2) were exclusively induced only in
the exosome-treated group;
• twenty-three genes (Prom1, Tiam1, Bcl2, Bax, Casp9, Hgf,
Jak2, Met, Mapk2k2, Alcam1, Eng, Flot2, Itga4, Itga6, Kit,
Pecam1, Thy, Cdc42, Casp8, Ets1, Myb,Map2k1, Mapk1) were
found to be upregulated both in the exosome and MSCPD-1+
cell treated groups;
• fourteen genes (Bmi1, Cd44, Itgb1, Muc1, Cdk4, Nras, Sat3,
Kitl, Raf1, Mtor, Akt1, Mapk3, Pik3ca, Rac1) were found to be
upregulated in all three groups.
Finally, it should be noted that the dramatic gene expression
alterations seen in the exosome-related groups were exclusively
due to the presence of the exosomes as the “MSCPD-1+ only”
cluster contained no genes (Figure 4F).
Melanoma-Derived Exosomes Promote
Tumorigenic and Cell Survival Signaling
Pathway(s)
Figure 5 shows the map of interaction pathways based on
overexpressed molecules (red symbols) in in vivo experiments.
We detected overexpressed elements of three main pathways
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FIGURE 3 | Exosome re-educated MSCs show oncogene dominance and PD-1 expression. (A) QRT-PCR analysis of 40 tumor-related genes in exosome-exposed
MSCs using a self-designed panel. The graph shows the relative expression values for each gene after 6, 24, and 72 h of exosome exposure. The trend line of altered
gene expression pattern (indicated by thick black line) shows an increasing tendency over time (mean ± SD). (B) QRT-PCR analysis of PD-1 in MSCs after 2 and 24 h
of exosome exposure. The graph represents mean + SEM (n = 3). (C) Representative immunoblot of PD-1 protein expression in control and exosome-exposed
MSCs after 24 h of exosome treatment. (D,E) Fluorescent immunocytochemistry of PD-1 in 24 h exosome-exposed MSC cultures, using a primary rat antibody to
PD-1 and a secondary AlexaFluor647-conjugated antibody to rat IgG (red). Nuclei were stained with DAPI. (D) α-tubulin network of cells was directly labeled by an
AlexaFluor488-conjugated antibody (green). Images were acquired by confocal microscopy. (E) Images were taken by STORM super-resolution microscopy. STORM
super-resolution imaging of PD-1 revealed that PD-1 was localized mostly around the nucleus, which were blurred and were not resolvable using diffraction-limited
confocal microscopy (D) of the same region.
which do participate in tumor progression and metastasis
formation (47). Using the IPA Path Designer Grow tool, we
generated an interaction map which contains proteins (or
their established complexes) encoded by the overexpressed
genes, and exosomal miRNAs and proteins (gray boxes)
which were previously shown to control or affect the marked
signaling molecules.
To demonstrate these results and to explore the potential
causative exosomal factors, we again performed an IPA. The
analysis allowed further refinement of the underlying molecular
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FIGURE 4 | Melanoma exosomes promote tumor progression and metastasis formation in vivo. (A) Tumor coverage of lungs on day 15 in different animal groups. The
graph represents mean + SD (n = 3). (B) Number of distant metastases on day 25. One dot represents one animal in each group, red lines show the average number
of metastases per animal. (C) FISH analysis of a paraortic lymph node metastases, which showed the presence of exosome-exposed MSC. Y chromosome (red dot)
of the male mouse-derived MSC was detected in the metastases of a female mouse. (D) Heatmap and cluster analysis of gene expression pattern, which show
protooncogenic dominance in exosome or MSCPD-1+ groups. Robust hierarchical clustering based on fold changes in the gene expression data between selected
groups divide the treated groups into several upper classes. Groups treated by exosomes or MSCPD-1+ were compared to untreated controls. Exosomes MSCPD-1+
treatments were closely related. (E) QRT-PCR analysis of PD-1 in the lung samples using TaqMan probes (n = 3). (F) The Venn diagram shows possible relations
between a finite collections of different sets of genes measured during gene expression profiling (D).
processes and pathways involved in the summarized effect of
this gene expression profile. The previously described 40-gene
QRT-PCR panel was enriched in genes related to cellular
movement and migration, cell survival and connective tissue
development and function, involving tumor cells. Additional
processes included growth and proliferation of tumor cells as
well as the PD-1:PD-L1 interaction (and its consequences).
Focusing on PD-1 and mTOR pathway, a network was
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FIGURE 5 | Integrated associative network of the in vivo overexpressed genes supplemented with the interacting exosomal factors. The network of overexpressed
genes (red symbols) was conceived by us based on literature data. The relationships between molecules were supported also by the IPA knowledge base. Network
visualization was performed using the Path Explorer tool of the IPA Path Designer. The exosomal proteins and miRNAs (gray boxes) were connected to elements of
the network by the Grow tool of the IPA Path Designer based on experimental data of the IPA knowledge base. Activation of the established network by exosomal
components may support the survival, migration, growth, and metastasis of tumor cells.
built from the overexpressed genes, and their complexes
known to be related to tumor progression using the Path
Explorer tool in the IPA Path Designer. Then a list was
generated that contained the exosomal proteins detected
by MS and the exosomal miRNAs identified by SOLiD
sequencing. The Grow tool in the IPA Path Designer revealed
significant interactions between the exosome-induced expression
network and the molecular content of these vesicles. The
resulting interaction network shows both direct and indirect
interactions, but it contains only experimentally observed
relationships based on the Ingenuity Knowledge Base. This
network demonstrates that 61 exosomal molecules (Table 4)
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TABLE 4 | List of exosomal proteins and miRNAs connected to the integrated associative network by IPA Path Designer.
ID Symbol Entrez gene name Symbol Seed regio ID
Q640N1 AEBP1 AE binding protein 1 let-7a-3p UAUACAA mmu-let-7a-1-3p, mmu-let-7b-3p
P48036 ANXA5 Annexin A5 mmu-let-7c-2-3p, mmu-let-7f-1-3p
P08226 APOE Apolipoprotein E let-7a-5p GAGGUAG mmu-let-7a-5p, mmu-let-7b-5p
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1 mmu-let-7c-5p, mmu-let-7d-5p
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 mmu-let-7e-5p, mmu-let-7f-5p
O55107 BSG Basigin (Ok blood group) mmu-let-7g-5p, mmu-mir-98-5p
Q9WVT6 CA14 Carbonic anhydrase 14 miR-100-5p ACCCGUA mmu-mir-99a-5p, mmu-mir-99b-5p
P41731 CD63 CD63 molecule miR-125b-5p CCCUGAG mmu-mir-125a-5p, mmu-mir-125b-5p
P35762 CD81 CD81 molecule mmu-mir-351-5p
P29812 DCT Dopachrome tautomerase miR-126a-5p AUUAUUA mmu-mir-126a-5p
Q3UAM9 ENG Endoglin miR-139-5p CUACAGU mmu-mir-139-5p
P17182 ENO1 Enolase 1 miR-16-5p AGCAGCA mmu-mir-15a-5p, mmu-mir-15b-5p
P19096 FASN Fatty acid synthase mmu-mir-16-5p, mmu-mir-195a-5p
P11276 FN1 Fibronectin 1 mmu-mir-322-5p, mmu-mir-497a-5p
P09528 FTH1 Ferritin heavy chain 1 miR-17-5p AAAGUGC mmu-mir-106b-5p, mmu-mir-17-5p
P16858 GAPDH glyceraldehyde-3-phosphate dehydrogenase mmu-mir-20a-5p, mmu-mir-93-5p
P08752 GNAI2 G protein subunit alpha i2 miR-181a-5p ACAUUCA mmu-mir-181a-5p, mmu-mir-181b-5p
Q3TAV1 GPNMB Glycoprotein nmb mmu-mir-181c-5p, mmu-mir-181d-5p
P19157 GSTP1 glutathione S-transferase pi 1 miR-18a-5p AAGGUGC mmu-mir-18a-5p
P11499 HSP90AB1 Heat shock protein 90 alpha family class B member 1 miR-193a-3p ACUGGCC mmu-mir-193a-3p
B1B0C7 HSPG2 Heparan sulfate proteoglycan 2 miR-199a-3p CAGUAGU mmu-mir-199a-3p, mmu-mir-199b-3p
P02468 LAMC1 Laminin subunit gamma 1 miR-199a-5p CCAGUGU mmu-mir-199a-5p, mmu-mir-199b-5p
Q3U2W5 LGALS8 Galectin 8 miR-19b-3p GUGCAAA mmu-mir-19a-3p,
P21956 MFGE8 Milk fat globule-EGF factor 8 protein mmu-mir-19b-3p
P62962 PFN1 Profilin 1 miR-21-5p AGCUUAU mmu-mir-21a-5p
P52480 PKM Pyruvate kinase, muscle miR-221-3p GCUACAU mmu-mir-222-3p
P17742 PPIA Peptidylprolyl isomerase A miR-223-3p GUCAGUU mmu-mir-223-3p
Q61171 PRDX2 Peroxiredoxin 2 miR-23a-3p UCACAUU mmu-mir-23a-3p
Q8CCG5 RALB RAS like proto-oncogene B mmu-mir-23b-3p
O08992 SDCBP Syndecan binding protein miR-30c-5p GUAAACA mmu-mir-30a-5p
Q0VGP2 SEMA3B Semaphorin 3B mmu-mir-30b-5p
P10852 SLC3A2 Solute carrier family 3 member 2 mmu-mir-30c-5p
Q3UQM7 SLC7A5 Solute carrier family 7 member 5 mmu-mir-30d-5p
O09044 SNAP23 Synaptosome associated protein 23 mmu-mir-30e-5p
Q64337 SQSTM1 Sequestosome 1 miR-330-5p CUCUGGG mmu-mir-326-3p
Q542D9 TFRC Transferrin receptor miR-34a-5p GGCAGUG mmu-mir-34a-5p
P39876 TIMP3 TIMP metallopeptidase inhibitor 3 mmu-mir-34b-5p
Q9R1Q6 TMEM176B Transmembrane protein 176B mmu-mir-34c-5p
Q3UCW0 TSG101 Tumor susceptibility 101 miR-7a-5p GGAAGAC mmu-mir-7a-5p
may affect tumor progression through pathways controlled by
key components including MET, Ras, RAF1, Mek, ERK1/2,
MITF, BCL2, PI3K, Akt, mTOR, PD-1, KIT, JAK STAT3,
or ETS1.
Taken together, these findings demonstrate that interaction
between exosomes and MSCs induces a tumor-like phenotype
with PD-1 overexpression of naïve MSC in vitro and a fast tumor
progression in vivo.
DISCUSSION
Considering the fact that metastatic complications are
responsible for almost 90% of cancer-driven mortality (48),
a deep understanding of tumor metastatic processes is one
of the most important challenges in both fundamental and
applied research directions in tumor biology. Whilst certain
organotropic aspects of tumor cells were addressed by Paget’s
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“seed-and-soil” hypothesis in the early nineteenth century (49),
the detailed description of the spatiotemporal characteristics
of the metastatic processes requires an extended model.
MSCs, as multipotent stromal cells, are important players in
dynamic tumor microenvironment (12). MSCs could stimulate
angiogenesis via paracrine signaling and participate in metastasis
formation to promote the epithelial-mesenchymal transition
(12). Consequently, in the last decade, numerous studies
suggested the importance of soluble and vesicle-like components
of the tumor microenvironment in epithelial-mesenchymal
transition as crucial factors in the metastatic establishment (50).
Among these, recent findings of intercellular communication
mechanisms unquestionably highlighted the crucial role of EVs
(e.g., exosomes) serving as “information packages” within the
coordinated cell-to-cell signaling (51).
In the current study, we demonstrate that MSCs, widely
abundant in solid tumors as well as in healthy tissues,
undergo a marked re-education process upon communication
with metastatic cancer cells via exosome-mediated information
transfer. This transformation process results in characteristic
response-patterns corresponding to a given cancerous cell
lines (12).
First, we intended to precisely define the EV population
which we later employed via in vitro and in vivo experimental
approaches. Besides applying the experimental requirements of
the International Society for Extracellular Vesicles (ISEV) (i.e.,
determination of shape, size distribution and protein markers)
(52), we thoroughly defined the miRNA and protein content of
melanoma exosomes. These systematic assays concluded that the
isolated vesicles contained factors, which may regulate signaling
pathways related to cell death and survival, cellular movement,
development and cell proliferation. Given the appropriate uptake
of these vesicles by the targeted, multipotent recipient cells, it is
highly probable that most signaling pathways mentioned above
were significantly affected. In accordance with previous results in
the literature, we showed successful internalization of exosomes
by recipient MSCs. As expected, following 72 h of exposure,
MSCs displayed accelerated proliferation presumably initiated
by the transforming exosome cargo. Moreover, melanoma
exosomes were able to hinder the induction of the cell death
response commonly triggered by TNFα. TNFα is a frequently
identified, soluble, tumor-suppressing factor in cancerous
microenvironments (53). This inhibition strongly suggested
that exosomes initialize and sustain malignant transformation
of MSCs.
Further, we described numerous, exosome-induced
phenotypic manifestation of the above malignant re-education
process in the recipient cells. Apart from identifying tumor
markers, the transformation of exposed cells is characterized
by markedly modified gene expression patterns. As discussed
previously, specific gene expression alterations are often
associated with specific steps of cancerous transformation.
Malignant cell lines possess altered expression of genes
responsible for apoptotic regulation (Bax, Bcl2, caspases),
regulating metastasis (integrins, ITGA2-6, ITGB1, KIT) or
various growth factors (ETS1, HGF, MET, etc.). Importantly,
we successfully identified two melanoma-specific markers,
i.e., MITF (Microphthalmia-associated transcription factor)
and MLANA (Melanoma antigen recognized by T-cells) in
the exosome-exposed MSCs. MLANA and its regulator MITF
play a fundamental role in melanocyte development, tumor
progression and are overexpressed in melanoma cells (54). The
presence of these markers in exosome-exposed MSCs shows
effective transfer of the encoded tumorigenic information, and
may have a pivotal role in disease progression. Besides, we also
identified a characteristic set of genes, belonging mostly to proto-
oncogenes, whose expression was significantly elevated upon
exosome treatment. Among these molecules, we emphasize the
increased expression of CD44 which was previously assigned as
cancer stem cell marker and of mTOR, a characteristic indicator
of the engagement of the PD-1:PD-L1 pathway (15). Indeed,
activation of mTOR signaling is particularly important. As it was
previously demonstrated by Kleffel et al., overexpression of PD-1
in exceptionally aggressive melanoma subpopulations facilitated
tumor progression by activating the mTOR signaling pathway
(actually, this response was highly unexpected compared to that
of the classic PD-1:PD-L1 dependent T-cell anergy, a crucial
aspect of immunotherapy in the clinics) (15). Quite strikingly,
in exosome treated MSCs, we detected a significant induction
of PD-1 and mTOR. These novel data strongly support that
these vesicles might trigger the formation of an aggressive,
melanoma-like subpopulation of re-educated recipient MSCs.
Our findings therefore propose that the re-educated
melanoma-like MSCPD-1+ subpopulation, originating from
multipotent tissue-derived MSCs, is an autonomous entity. It is
characterized by typical properties of cancerous transformation
such as hyperproliferation, resistance to apoptosis, expression
of melanoma markers, proto-oncogenic gene expression
patterns, and PD-1 over-expression. Indeed, those melanoma
exosomes that induced in vitro generation of the melanoma-like
MSCPD-1+ cells, also facilitated in vivo metastasis formation in
the lungs or other distant organs of treated animals. Actually,
our findings that melanoma exosomes or exosome re-educated
MSCPD-1+ promote tumor progression, are in good accordance
with previous finding of Kleffel et al. describing that shRNA
or antibody mediated inhibition of PD-1 signaling inhibits
metastasis formation and tumor progression in experimental
animals (15). Assessment of the expression patterns of genes
related to tumor progression in the exposed animal tissues
revealed numerous cases of exosome-induced overexpression;
this supports our hypothesis that melanoma exosomes should be
considered as oncosomes (6).
Our results also demonstrated that melanoma exosomes
also generated a characteristic signaling pattern in MSCPD-1+
recipient population. As it was shown in numerous studies
PI3K/Akt, Ras/MAPK, and STAT3 pathways are commonly
activated in tumor cells (47, 55). In this study, based on
our in vitro and in vivo results and literature data, we
introduce a novel, comprehensive network of common tumor-
related proteins, such as PD-1, MET, RAF1, STAT3, BCL2,
or mTOR. The network highlights not only the relationship
of these elements, but also contains upstream exosomal
regulating factors which may contribute to the activation
of tumorigenic signaling, and hence, fast tumor progression.
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According to our best knowledge, this associative network
between overexpressed genes and the potential exosomal
inducers, is the first tumor progression signaling pattern which
connected experimental response-patterns with experimentally
detected exosomal-molecular-patterns. Further, our data also
indicate that the above complexity of exosomal communication
requires system-level approaches.
Finally, it is important to note that our conclusions are
not based on in silico predictions exclusively, but rather on
carefully designed and systematically executed in vitro and
in vivo experiments, all suggesting that the specific, robust,
molecular content of the isolated exosomes can indeed generate
a unique intercellular niche responsible for the re-education
of neighboring cells via oncogenic transformation. These re-
educated melanoma-like MSCPD-1+ cells, in turn, facilitate
metastatic disease progression via ignition of a complex series of
subsequent events both locally and systematically. Thus, based
on our results and recently published, additional evidences about
exosomes, there is an urgent demand to supplement and extend
the outdated “seed-and-soil” hypothesis with the oncosome-
driven re-education process.
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